Elizabeta Nemeth, Ph.D.
Elizabeta Nemeth is a co-founder of Intrinsic LifeSciences. She holds a Ph.D. in Molecular, Cellular and Neurosciences from the University of Hawaii. Elizabeta joined UCLA in 2002, and has been studying the biology of the iron regulatory peptide hepcidin.
Together with Tomas Ganz, she developed the first human hepcidin assay. She has made major contributions to the understanding of iron homeostasis and its dysregulation in many diseases, including inflammatory disorders, thalassemias, and iron overload diseases. In 2007, Elizabeta received the Grace Goldsmith Award from the American College of Nutrition for “significant achievements in the field of nutrition by a scientist under the age of 50 years”.
Elizabeta Nemeth’s Selected Publications:
- • Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice.
- • Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.
- • Hepcidin and disorders of iron metabolism.
- • The molecular basis of hepcidin-resistant hereditary hemochromatosis.
- • Immunoassay for human serum hepcidin.
- • Liver iron concentrations and urinary hepcidin in beta-thalassemia.
- • The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study.
- • Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.
- • IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.
- • Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.
For the full list of publications, click here http://www.ncbi.nlm.nih.gov/pubmed?term=hepcidin%20OR%20ferroportin%20AND%20nemeth